Q2 EPS Estimates for Editas Medicine Decreased by Analyst

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities researchers at Zacks Research decreased their Q2 2026 earnings per share (EPS) estimates for shares of Editas Medicine in a report released on Monday, March 23rd. Zacks Research analyst Team now expects that the company will earn ($0.34) per share for the quarter, down from their prior estimate of ($0.33). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine’s Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.36) EPS.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.21. The firm had revenue of $24.74 million for the quarter, compared to analyst estimates of $8.77 million. Editas Medicine had a negative net margin of 395.02% and a negative return on equity of 389.73%.

EDIT has been the topic of several other reports. Chardan Capital reaffirmed a “buy” rating and issued a $3.50 price objective on shares of Editas Medicine in a research report on Monday, March 9th. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a report on Monday, March 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research note on Wednesday, January 21st. JonesTrading upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Tuesday, March 10th. Finally, Robert W. Baird set a $6.00 price objective on Editas Medicine in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $5.30.

Editas Medicine Stock Down 6.3%

Shares of EDIT stock opened at $2.25 on Wednesday. Editas Medicine has a 12-month low of $0.91 and a 12-month high of $4.54. The firm has a fifty day moving average of $2.09 and a 200-day moving average of $2.56. The company has a market capitalization of $220.21 million, a price-to-earnings ratio of -1.19 and a beta of 2.16.

Hedge Funds Weigh In On Editas Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of EDIT. Captrust Financial Advisors bought a new stake in Editas Medicine in the second quarter valued at approximately $26,000. StoneX Group Inc. bought a new position in shares of Editas Medicine during the 4th quarter worth approximately $33,000. Victory Capital Management Inc. bought a new position in shares of Editas Medicine during the 3rd quarter worth approximately $36,000. Sei Investments Co. acquired a new position in shares of Editas Medicine during the 3rd quarter worth approximately $46,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Editas Medicine during the 3rd quarter worth approximately $50,000. Institutional investors own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.